|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C22orf39 |
Gene summary for C22ORF39 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C22orf39 | Gene ID | 128977 |
| Gene name | chromosome 22 open reading frame 39 | |
| Gene Alias | C22orf39 | |
| Cytomap | 22q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q6P5X5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 128977 | C22orf39 | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.37e-03 | 2.05e-01 | -0.1808 |
| 128977 | C22orf39 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.96e-02 | 1.28e-01 | -0.1088 |
| 128977 | C22orf39 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.02e-14 | 2.73e-01 | -0.1954 |
| 128977 | C22orf39 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.46e-03 | 1.44e-01 | -0.1207 |
| 128977 | C22orf39 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.79e-04 | 2.30e-01 | -0.1526 |
| 128977 | C22orf39 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.96e-07 | 2.04e-01 | -0.1464 |
| 128977 | C22orf39 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.63e-07 | 1.99e-01 | -0.059 |
| 128977 | C22orf39 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.83e-05 | 1.98e-01 | -0.0842 |
| 128977 | C22orf39 | HTA11_7663_2000001011 | Human | Colorectum | SER | 6.81e-04 | 2.82e-01 | 0.0131 |
| 128977 | C22orf39 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.41e-06 | 4.68e-01 | 0.0171 |
| 128977 | C22orf39 | HTA11_10711_2000001011 | Human | Colorectum | AD | 6.02e-03 | 1.43e-01 | 0.0338 |
| 128977 | C22orf39 | HTA11_7469_2000001011 | Human | Colorectum | AD | 2.39e-03 | 3.31e-01 | -0.0124 |
| 128977 | C22orf39 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.39e-09 | 2.23e-01 | 0.294 |
| 128977 | C22orf39 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.40e-05 | 4.84e-01 | 0.3487 |
| 128977 | C22orf39 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.92e-08 | 2.58e-01 | 0.3859 |
| 128977 | C22orf39 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 5.79e-04 | 1.68e-01 | 0.2585 |
| 128977 | C22orf39 | LZE2T | Human | Esophagus | ESCC | 4.15e-07 | 1.02e+00 | 0.082 |
| 128977 | C22orf39 | LZE4T | Human | Esophagus | ESCC | 7.29e-12 | 4.56e-01 | 0.0811 |
| 128977 | C22orf39 | LZE7T | Human | Esophagus | ESCC | 1.79e-12 | 6.67e-01 | 0.0667 |
| 128977 | C22orf39 | LZE8T | Human | Esophagus | ESCC | 2.55e-02 | 1.61e-01 | 0.067 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C22orf39 | SNV | Missense_Mutation | c.101G>T | p.Gly34Val | p.G34V | Q6P5X5 | protein_coding | tolerated_low_confidence(0.14) | benign(0.089) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C22orf39 | SNV | Missense_Mutation | novel | c.371N>T | p.Pro124Leu | p.P124L | Q6P5X5 | protein_coding | tolerated(0.86) | benign(0.003) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C22orf39 | SNV | Missense_Mutation | rs754147776 | c.424N>A | p.Glu142Lys | p.E142K | Q6P5X5 | protein_coding | tolerated(0.7) | benign(0.01) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C22orf39 | SNV | Missense_Mutation | c.344N>A | p.Ala115Glu | p.A115E | Q6P5X5 | protein_coding | tolerated(0.51) | benign(0.109) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| C22orf39 | SNV | Missense_Mutation | novel | c.145C>T | p.Pro49Ser | p.P49S | Q6P5X5 | protein_coding | tolerated(0.09) | possibly_damaging(0.73) | TCGA-DD-AAVP-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| C22orf39 | SNV | Missense_Mutation | novel | c.370N>G | p.Pro124Ala | p.P124A | Q6P5X5 | protein_coding | tolerated(0.31) | benign(0.167) | TCGA-BA-4076-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |